Dec 2016 $33 M No. 8 $10 to $50 million 98
IRX Therapeutics Inc: Raise no. 8, Dec 2016 × Investors in this round 98 investors had bought by the notice of Aug 29, 2017: 98 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $33 M of $33 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Curtis P. Robb · Executive Officer Mark W. Leuchtenberger · Executive Officer, Director Monil W. Shah · Executive Officer Zygmund P. Roth · Executive Officer Charles R. Cherington · Director David H. Deming · Director Edmund W. Truell · Director Ferid D. Murad · Director George P. Denny III · Director John D. Halpern · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 29, 2017. Read the notice at the SEC .
equity SEC Oct 2016 $6 M No. 7 $2 to $10 million 4
IRX Therapeutics Inc: Raise no. 7, Oct 2016 × Investors in this round 4 investors had bought by the notice of Nov 9, 2016: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $8 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Curtis P. Robb · Executive Officer Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer, Director Zygmund P. Roth · Executive Officer Charles R. Cherington · Director David H. Deming · Director Ferid D. Murad · Director George P. Denny III · Director John D. Halpern · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 9, 2016. Read the notice at the SEC .
debt, options SEC Apr 2016 $2 M No. 6 $2 to $10 million 1
IRX Therapeutics Inc: Raise no. 6, Apr 2016 × Investors in this round 1 investor had bought by the notice of May 13, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $15 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Curtis P. Robb · Executive Officer Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer, Director Zygmund P. Roth · Executive Officer Charles R. Cherington · Director David H. Deming · Director Ferid D. Murad · Director George P. Denny III · Director John D. Halpern · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Hwang, President. Source: SEC Form D, newest notice filed May 13, 2016. Read the notice at the SEC .
debt, options SEC Dec 2014 $41 M No. 5 $10 to $50 million 230
IRX Therapeutics Inc: Raise no. 5, Dec 2014 × Investors in this round 230 investors had bought by the notice of Aug 17, 2015: 230 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $41 M of $41 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Curtis P. Robb · Executive Officer Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer, Director Zygmund P. Roth · Executive Officer David H. Deming · Director Ferid D. Murad · Director George P. Denny III · Director John D. Halpern · Director John T. Spitznagel · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2015. Read the notice at the SEC .
equity SEC Feb 2014 $15 M No. 4 $10 to $50 million 104
IRX Therapeutics Inc: Raise no. 4, Feb 2014 × Investors in this round 104 investors had bought by the notice of Mar 14, 2014: 104 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $18 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Curtis P. Robb · Executive Officer Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer, Director Zygmund P. Roth · Executive Officer David H. Deming · Director Ferid D. Murad · Director George P. Denny III · Director John D. Halpern · Director John T. Spitznagel · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC .
debt, options SEC May 2012 $2 M No. 3 Under $2 million 105
IRX Therapeutics Inc: Raise no. 3, May 2012 × Investors in this round 105 investors had bought by the notice of May 30, 2012: 105 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $50,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer, Director Ferid W. Murad · Director John T. Spitznagel · Director John W. Hadden · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed May 30, 2012. Read the notice at the SEC .
debt, options SEC May 2010 $8 M No. 2 $2 to $10 million 163
IRX Therapeutics Inc: Raise no. 2, May 2010 × Investors in this round 163 investors had bought by the notice of Jun 11, 2010: 163 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Hwang · Executive Officer John W. Hadden II · Executive Officer Ferid W. Murad · Director Frank J. Loverro · Director Howard H. Stevenson · Director John T. Spitznagel · Director John W. Hadden · Director Lawrence M. Wolf · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Jun 11, 2010. Read the notice at the SEC .
debt, options SEC Oct 2009 $2 M No. 1 $2 to $10 million 33
IRX Therapeutics Inc: Raise no. 1, Oct 2009 × Investors in this round 33 investors had bought by the notice of Jan 11, 2010: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $6 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Hwuang · Executive Officer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Jan 11, 2010. Read the notice at the SEC .
equity, options SEC